DOI: 10.1128/JCM.43.11.5425-5427.2005
Article Figures & Data
Tables
- TABLE 1.
Species distribution of Candida isolates by geographic region
Species % by regiona APAC (354 isolates) LAM (542 isolates) EU (668 isolates) NAM (671 isolates) Total (2,235 isolates) C. albicans 56.2 44.3 61.7 49.2 52.8 C. tropicalis 16.1 20.8 8.4 7.7 12.4 C. parapsilosis 15.3 18.1 10.9 15.4 14.7 C. glabrata 8.0 4.8 10.2 21.3 11.9 C. krusei 1.1 1.6 5.2 1.6 2.6 C. guilliermondii 1.4 7.6 0.9 0.8 2.6 C. lusitaniae 1.1 0.6 1.1 3.0 1.5 C. kefyr 0.6 1.3 0.4 0.7 Candida spp.b 0.8 1.6 0.3 0.6 0.8 - TABLE 2.
In vitro susceptibilities of 2,235 clinical isolates of Candida spp. to anidulafungina
Organism No. tested Cumulative % susceptible at: 0.007 μg/ml 0.015 μg/ml 0.03 μg/ml 0.06 μg/ml 0.12 μg/ml 0.25 μg/ml 0.5 μg/ml 1 μg/ml 2 μg/ml 4 μg/ml 8 μg/ml C. albicans 1,181 4 28 61 88 99 99 99 99 100 C. glabrata 265 1 19 70 97 100 C. tropicalis 278 1 25 72 94 98 99 99 99 100 C. krusei 59 5 64 95 100 C. kefyr 15 7 67 100 C. parapsilosis 328 1 1 1 1 2 6 39 97 100 C. guilliermondii 57 2 5 9 60 93 100 C. lusitaniae 34 12 59 97 100 Candida spp. 18 6 13 13 25 31 56 94 94 100 Total 2,235 2 18 45 70 80 82 83 89 99 99 100 ↵ a Broth microdilution testing according to CLSI M27-A2 (10), using 24-h incubation and MIC-2 endpoint.
- TABLE 3.
In vitro activity of anidulafungin against 315 fluconazole-resistant clinical isolates of Candida spp.a
Organism No. tested Cumulative % susceptible to anidulafungin at: 0.007 μg/ml 0.015 μg/ml 0.03 μg/ml 0.06 μg/ml 0.12 μg/ml 0.25 μg/ml 0.5 μg/ml 1 μg/ml 2 μg/ml 4 μg/ml 8 μg/ml C. albicans 41 15 42 66 95 95 95 98 100 C. glabrata 110 1 3 36 81 98 100 C. krusei 146 1 3 40 82 97 99 100 Candida spp. 18 6 17 39 39 39 44 67 83 100 Total 315 3 9 42 81 94 96 98 99 100 ↵ a Broth microdilution testing was done according to CLSI M27-A2 (10), using 24-h incubation and MIC-2 endpoint. Fluconazole resistance is defined as a MIC of ≥64 μg/ml.
